Follow
'Using two independent real-world datasets from three different countries and an independent validation cohort based on the global, double-blind, placebo-controlled, phase 3 RECOURSE trial, we demonstrate that codon-specific KRAS mutations predict OS benefit for patients treated with the chemotherapeutic agent FTD/TPI in late-stage mCRC.'
